PIA Executive Committee:
Co-Chair: Corinne Fischer, MD
Dr. Fischer is a staff psychiatrist with the Mental Health Service at St. Michael’s Hospital and director of Geriatric Psychiatry at St. Michael’s Hospital. She is an associate scientist and co-director of Neurodegenerative Research, Division of Neuroscience Research, at the Keenan Research Centre for Biomedical Research, the Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Canada. She has an academic appointment as Associate Professor at the University of Toronto in the Division of Geriatric Psychiatry and is an associate member of the Institute of Medical Science where she supervises graduate students, research fellows, residents and medical students. She was recently appointed an associate editor of the Journal of Alzheimer’s disease and elected academic co-chair of the Neuropsychiatric Symptom Professional Interest Area ISTAART in addition to being a member of several national/international organizations including CAGP, AAGP, IPA and ISTAART. Dr. Fischer’s main clinical and research focus centres around neuropsychiatric symptoms in Alzheimer’s disease and their clinical, imaging and pathological correlates. She directs the St. Michael’s Hospital Memory Clinic and is a member of the Toronto Dementia Research Alliance as well as the Behavioural Neurology Section at the University of Toronto. She is a principal investigator for a number of peer-reviewed grants as well as a site PI for several large multi-centred grants funded by Brain Canada, the Ontario Brain Institute and the Weston Foundation. She has approximately sixty peer-reviewed publications and has presented her work extensively at national and international meetings.
Co-Chair: Ross A. Baker, PhD, MBA
Director, CNS Global Medical Affairs
Otsuka Pharmaceutical Development and Commercialization
Ross has 20 years of experience in the pharmaceutical industry, with 4 years on the provider side, and 16 years in positions of increasing responsibility in CNS medical affairs groups at Organon, Bristol-Myers Squibb, and Otsuka. Ross has authored over 60 peer reviewed publications, and more than 200 abstracts and posters presented at scientific congresses. At Otsuka, his primary focus is to support the clinical development programs for brexpiprazole in the treatment of agitation in Alzheimer’s and invisible war wounds (i.e, PTSD).
Ross received his B.S. degree in Biology/Psychology from Muhlenberg College. He earned his PhD degree in Biomedical Science from the University of Connecticut School of Medicine and his MBA degree in Finance from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. He also worked as a post-doctoral fellow at the National Institute of Mental Health and as a research scientist at the University of Pittsburgh School of Medicine.
Communications Chair: Jennifer R. Gatchel, PhD, MD
Jennifer Gatchel is a Geriatric Psychiatrist physician scientist and an Assistant Psychiatrist in the Department of Psychiatry at Massachusetts General Hospital and the Division of Geriatric Psychiatry, Harvard Medical School. Her research interests are focused on understanding the relationships among Alzheimer’s Disease (AD)-associated proteins amyloid and tau, neuropsychiatric symptoms, and cognitive decline in the preclinical and prodromal stages of AD and related dementias. She is utilizing a combination of neuroimaging and cognitive assessments towards developing better prevention and treatment strategies for individuals at risk for AD. She is also interested in neuromodulation in the treatment of mood and cognitive disorders. Her body of work has been recognized by the National Institutes of Health, the BrightFocus Foundation, and the Alzheimer’s Association. Jennifer’s innovative research program is complemented by her leadership roles advocating for patients with dementia, promoting healthy brain aging, and training the next generation of Geriatric Psychiatrists.
Member-in-Training: Willem S. Eikelboom, MSc.
Willem Eikelboom is a neuropsychologists and works as PhD candidate at the Alzheimer Center of the Erasmus University Medical Center in Rotterdam, the Netherlands. He obtained his Master Degree in Healthcare Psychology and started his PhD in the beginning of 2018. Since then, most of his research focuses on the early detection and appropriate treatment of neuropsychiatric syndromes in the Alzheimer’s disease. He is one of the researchers involved in the ‘Behavioral symptoms in Alzheimer’s disease, Towards early Identification and Treatment’ (BEAT-IT) project. This multi-center project consists of studies ranging from the neurobiological underlying mechanisms of neuropsychiatric symptoms to the deliverance of non-pharmacological strategies to reduce these symptoms. He is currently coordinating an intervention study that evaluates the use of the DICE method to structure and standardize the assessment and management of neuropsychiatric symptoms in memory clinics in Rotterdam area. He is member of the Dutch Society for Neuropsychology and joined the Neuropsychiatric Syndromes PIA Executive Committee in 2019.